Financial

Shockwave Medical Reports Second Quarter 2022 Financial Results

SANTA CLARA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2022. Recent Highlights Recognized revenue of $120.7 million […]

Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results

Over $300 Million in Capital Added to Balance Sheet, Supporting an Operating Runway into Second Half of 2025 Patient Dosing Underway with Lead Candidate, VERVE-101, for Treatment of Heterozygous Familial Hypercholesterolemia; Regulatory Clearances in the United Kingdom and United States Anticipated in Second Half of 2022 Preclinical Data Supporting Nomination […]

scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022 Continued to advance commercial readiness activities in support of an anticipated Q4 2022 launch of FUROSCIX, if approved Ended Q2 with cash, cash equivalents, restricted cash and investments of $56.0 million […]

InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update

– Generated 47.8% growth in CGuard™ revenue year-over-year – – Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission – – Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor to the company – — Management to Host Investor Conference […]

Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update

REN-001 IND submission planned for the second half of 2022 Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus infusion published in Journal of the American College of Cardiology: Basic to Translational Science CAMBRIDGE, Mass.–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused […]

CinCor Reports Second Quarter Financial Results and Provides Corporate Update

Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension Completed enrollment in the HALO Phase 2 trial for baxdrostat in patients with uncontrolled hypertension with 249 patients randomized; topline data expected in the second half […]